SG174471A1

SG174471A1 - Culture of pluripotent and multipotent cells on microcarriers

Culture of pluripotent and multipotent cells on microcarriers Download PDF

Info

Publication number: SG174471A1
Authority: SG; Singapore
Prior art keywords: cells; culture; microcarriers; passages; pluripotent
Prior art date: 2009-03-20

Application number

SG2011067725A

Other languages

English (en)

Inventor

Steve Oh

Allen Chen

Andre Choo

Shaul Reuveny

Original Assignee

Agency Science Tech & Res

Priority date

2009-03-20

Filing date

2010-03-12

Publication date

2011-10-28

2010-03-12 Application filed by Agency Science Tech & Res filed Critical Agency Science Tech & Res

2011-10-28 Publication of SG174471A1 publication Critical patent/SG174471A1/en

Links

210000002894 multi-fate stem cell Anatomy 0.000 title claims abstract description 91
238000000034 method Methods 0.000 claims abstract description 233
239000011435 rock Substances 0.000 claims abstract description 135
239000003112 inhibitor Substances 0.000 claims abstract description 133
238000004114 suspension culture Methods 0.000 claims abstract description 47
238000012258 culturing Methods 0.000 claims abstract description 36
238000000338 in vitro Methods 0.000 claims abstract description 25
210000004027 cell Anatomy 0.000 claims description 421
210000000130 stem cell Anatomy 0.000 claims description 224
239000011159 matrix material Substances 0.000 claims description 78
210000001671 embryonic stem cell Anatomy 0.000 claims description 76
230000004069 differentiation Effects 0.000 claims description 69
NGOGFTYYXHNFQH-UHFFFAOYSA-N fasudil Chemical compound C=1C=CC2=CN=CC=C2C=1S(=O)(=O)N1CCCNCC1 NGOGFTYYXHNFQH-UHFFFAOYSA-N 0.000 claims description 55
229960002435 fasudil Drugs 0.000 claims description 52
238000000576 coating method Methods 0.000 claims description 51
XHVAWZZCDCWGBK-WYRLRVFGSA-M Aurothioglucose Chemical compound OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O XHVAWZZCDCWGBK-WYRLRVFGSA-M 0.000 claims description 48
229960001799 aurothioglucose Drugs 0.000 claims description 47
229920002678 cellulose Polymers 0.000 claims description 47
239000001913 cellulose Substances 0.000 claims description 47
239000011248 coating agent Substances 0.000 claims description 47
239000000203 mixture Substances 0.000 claims description 41
210000002242 embryoid body Anatomy 0.000 claims description 33
IYOZTVGMEWJPKR-IJLUTSLNSA-N Y-27632 Chemical compound C1C[C@@H]([C@H](N)C)CC[C@@H]1C(=O)NC1=CC=NC=C1 IYOZTVGMEWJPKR-IJLUTSLNSA-N 0.000 claims description 30
ZAVGJDAFCZAWSZ-UHFFFAOYSA-N hydroxyfasudil Chemical compound C1=CC=C2C(O)=NC=CC2=C1S(=O)(=O)N1CCCNCC1 ZAVGJDAFCZAWSZ-UHFFFAOYSA-N 0.000 claims description 30
239000001963 growth medium Substances 0.000 claims description 27
108010035532 Collagen Proteins 0.000 claims description 18
102000008186 Collagen Human genes 0.000 claims description 18
102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 18
108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 18
229920001436 collagen Polymers 0.000 claims description 18
239000004017 serum-free culture medium Substances 0.000 claims description 18
210000002744 extracellular matrix Anatomy 0.000 claims description 17
229920002307 Dextran Polymers 0.000 claims description 15
241000288906 Primates Species 0.000 claims description 15
238000012136 culture method Methods 0.000 claims description 15
239000003636 conditioned culture medium Substances 0.000 claims description 14
108010085895 Laminin Proteins 0.000 claims description 10
102000007547 Laminin Human genes 0.000 claims description 10
210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 10
AWDORCFLUJZUQS-ZDUSSCGKSA-N (S)-2-methyl-1-(4-methylisoquinoline-5-sulfonyl)-1,4-diazepane Chemical compound C[C@H]1CNCCCN1S(=O)(=O)C1=CC=CC2=CN=CC(C)=C12 AWDORCFLUJZUQS-ZDUSSCGKSA-N 0.000 claims description 9
229920002971 Heparan sulfate Polymers 0.000 claims description 9
210000004504 adult stem cell Anatomy 0.000 claims description 9
210000004748 cultured cell Anatomy 0.000 claims description 8
108010067306 Fibronectins Proteins 0.000 claims description 7
102000016359 Fibronectins Human genes 0.000 claims description 7
CZQHHVNHHHRRDU-UHFFFAOYSA-N LY294002 Chemical compound C1=CC=C2C(=O)C=C(N3CCOCC3)OC2=C1C1=CC=CC=C1 CZQHHVNHHHRRDU-UHFFFAOYSA-N 0.000 claims description 7
229920002674 hyaluronan Polymers 0.000 claims description 7
239000004033 plastic Substances 0.000 claims description 7
229920003023 plastic Polymers 0.000 claims description 7
150000003839 salts Chemical class 0.000 claims description 7
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 6
229920000159 gelatin Polymers 0.000 claims description 6
235000019322 gelatine Nutrition 0.000 claims description 6
239000011521 glass Substances 0.000 claims description 6
229960003160 hyaluronic acid Drugs 0.000 claims description 6
LLJRXVHJOJRCSM-UHFFFAOYSA-N 3-pyridin-4-yl-1H-indole Chemical compound C=1NC2=CC=CC=C2C=1C1=CC=NC=C1 LLJRXVHJOJRCSM-UHFFFAOYSA-N 0.000 claims description 5
108010010803 Gelatin Proteins 0.000 claims description 5
108010039918 Polylysine Proteins 0.000 claims description 5
239000004793 Polystyrene Substances 0.000 claims description 5
150000002148 esters Chemical class 0.000 claims description 5
239000008273 gelatin Substances 0.000 claims description 5
235000011852 gelatine desserts Nutrition 0.000 claims description 5
230000001939 inductive effect Effects 0.000 claims description 5
229920000656 polylysine Polymers 0.000 claims description 5
229920002223 polystyrene Polymers 0.000 claims description 5
229940002612 prodrug Drugs 0.000 claims description 5
239000000651 prodrug Substances 0.000 claims description 5
229920001287 Chondroitin sulfate Polymers 0.000 claims description 4
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 4
108010031318 Vitronectin Proteins 0.000 claims description 4
102100035140 Vitronectin Human genes 0.000 claims description 4
108010008217 nidogen Proteins 0.000 claims description 4
229910021653 sulphate ion Inorganic materials 0.000 claims description 4
GBOKNHVRVRMECW-UHFFFAOYSA-N 1-pyridin-4-yl-3-(2,4,6-trichlorophenyl)urea Chemical compound ClC1=CC(Cl)=CC(Cl)=C1NC(=O)NC1=CC=NC=C1 GBOKNHVRVRMECW-UHFFFAOYSA-N 0.000 claims description 3
108010014258 Elastin Proteins 0.000 claims description 3
102000016942 Elastin Human genes 0.000 claims description 3
102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 claims description 3
102100037369 Nidogen-1 Human genes 0.000 claims description 3
102000007327 Protamines Human genes 0.000 claims description 3
108010007568 Protamines Proteins 0.000 claims description 3
108090000054 Syndecan-2 Proteins 0.000 claims description 3
239000000919 ceramic Substances 0.000 claims description 3
229920002549 elastin Polymers 0.000 claims description 3
150000002734 metacrylic acid derivatives Chemical class 0.000 claims description 3
229920001296 polysiloxane Polymers 0.000 claims description 3
229940048914 protamine Drugs 0.000 claims description 3
PODOAIWAYUVDEF-UHFFFAOYSA-N (2,4,6-trichlorophenyl)urea Chemical compound NC(=O)NC1=C(Cl)C=C(Cl)C=C1Cl PODOAIWAYUVDEF-UHFFFAOYSA-N 0.000 claims description 2
239000002245 particle Substances 0.000 description 158
108010082117 matrigel Proteins 0.000 description 58
IDDDVXIUIXWAGJ-DDSAHXNVSA-N 4-[(1r)-1-aminoethyl]-n-pyridin-4-ylcyclohexane-1-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1CC([C@H](N)C)CCC1C(=O)NC1=CC=NC=C1 IDDDVXIUIXWAGJ-DDSAHXNVSA-N 0.000 description 41
230000014509 gene expression Effects 0.000 description 41
210000001519 tissue Anatomy 0.000 description 37
102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 34
101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 34
230000012010 growth Effects 0.000 description 32
230000000644 propagated effect Effects 0.000 description 31
239000011324 bead Substances 0.000 description 29
239000002609 medium Substances 0.000 description 26
210000001778 pluripotent stem cell Anatomy 0.000 description 26
108090000623 proteins and genes Proteins 0.000 description 25
230000000694 effects Effects 0.000 description 22
230000007774 longterm Effects 0.000 description 22
206010028980 Neoplasm Diseases 0.000 description 21
229920005654 Sephadex Polymers 0.000 description 19
239000012507 Sephadex™ Substances 0.000 description 19
239000000463 material Substances 0.000 description 18
241000699666 Mus <mouse, genus> Species 0.000 description 16
230000015572 biosynthetic process Effects 0.000 description 16
238000004113 cell culture Methods 0.000 description 16
230000010261 cell growth Effects 0.000 description 16
239000003550 marker Substances 0.000 description 16
108010041788 rho-Associated Kinases Proteins 0.000 description 16
102000000568 rho-Associated Kinases Human genes 0.000 description 16
239000000725 suspension Substances 0.000 description 16
201000011510 cancer Diseases 0.000 description 14
239000010410 layer Substances 0.000 description 14
210000002459 blastocyst Anatomy 0.000 description 13
150000001875 compounds Chemical class 0.000 description 13
230000037361 pathway Effects 0.000 description 13
230000001902 propagating effect Effects 0.000 description 13
102000004169 proteins and genes Human genes 0.000 description 13
238000011160 research Methods 0.000 description 13
229920002684 Sepharose Polymers 0.000 description 12
238000013019 agitation Methods 0.000 description 12
230000035755 proliferation Effects 0.000 description 12
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 11
102000003974 Fibroblast growth factor 2 Human genes 0.000 description 11
238000007792 addition Methods 0.000 description 11
210000002950 fibroblast Anatomy 0.000 description 11
230000005764 inhibitory process Effects 0.000 description 11
235000018102 proteins Nutrition 0.000 description 11
239000003590 rho kinase inhibitor Substances 0.000 description 11
238000001878 scanning electron micrograph Methods 0.000 description 11
239000000126 substance Substances 0.000 description 11
210000004602 germ cell Anatomy 0.000 description 10
230000006698 induction Effects 0.000 description 10
210000002901 mesenchymal stem cell Anatomy 0.000 description 10
230000001105 regulatory effect Effects 0.000 description 10
210000004413 cardiac myocyte Anatomy 0.000 description 9
238000010790 dilution Methods 0.000 description 9
239000012895 dilution Substances 0.000 description 9
210000001900 endoderm Anatomy 0.000 description 9
108091003079 Bovine Serum Albumin Proteins 0.000 description 8
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 8
241001465754 Metazoa Species 0.000 description 8
108091000080 Phosphotransferase Proteins 0.000 description 8
238000004458 analytical method Methods 0.000 description 8
230000008878 coupling Effects 0.000 description 8
238000010168 coupling process Methods 0.000 description 8
238000005859 coupling reaction Methods 0.000 description 8
230000006378 damage Effects 0.000 description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
210000002257 embryonic structure Anatomy 0.000 description 8
230000002255 enzymatic effect Effects 0.000 description 8
239000003102 growth factor Substances 0.000 description 8
102000020233 phosphotransferase Human genes 0.000 description 8
239000000047 product Substances 0.000 description 8
238000002560 therapeutic procedure Methods 0.000 description 8
-1 4-methyl-5-isoquinolinyl Chemical group 0.000 description 7
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 7
102000029816 Collagenase Human genes 0.000 description 7
108060005980 Collagenase Proteins 0.000 description 7
102000001253 Protein Kinase Human genes 0.000 description 7
108090000315 Protein Kinase C Proteins 0.000 description 7
102000003923 Protein Kinase C Human genes 0.000 description 7
210000001109 blastomere Anatomy 0.000 description 7
229960002424 collagenase Drugs 0.000 description 7
201000010099 disease Diseases 0.000 description 7
230000001605 fetal effect Effects 0.000 description 7
230000001404 mediated effect Effects 0.000 description 7
238000010899 nucleation Methods 0.000 description 7
239000002243 precursor Substances 0.000 description 7
238000002360 preparation method Methods 0.000 description 7
108060006633 protein kinase Proteins 0.000 description 7
210000002966 serum Anatomy 0.000 description 7
210000001082 somatic cell Anatomy 0.000 description 7
230000010473 stable expression Effects 0.000 description 7
239000000758 substrate Substances 0.000 description 7
239000004971 Cross linker Substances 0.000 description 6
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 6
229920002683 Glycosaminoglycan Polymers 0.000 description 6
239000000427 antigen Substances 0.000 description 6
108091007433 antigens Proteins 0.000 description 6
102000036639 antigens Human genes 0.000 description 6
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
230000004071 biological effect Effects 0.000 description 6
230000001413 cellular effect Effects 0.000 description 6
229940127089 cytotoxic agent Drugs 0.000 description 6
238000009795 derivation Methods 0.000 description 6
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
238000010494 dissociation reaction Methods 0.000 description 6
230000005593 dissociations Effects 0.000 description 6
229940079593 drug Drugs 0.000 description 6
239000003814 drug Substances 0.000 description 6
210000003981 ectoderm Anatomy 0.000 description 6
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
238000012423 maintenance Methods 0.000 description 6
210000001161 mammalian embryo Anatomy 0.000 description 6
210000003716 mesoderm Anatomy 0.000 description 6
239000001301 oxygen Substances 0.000 description 6
229910052760 oxygen Inorganic materials 0.000 description 6
239000002953 phosphate buffered saline Substances 0.000 description 6
230000026731 phosphorylation Effects 0.000 description 6
238000006366 phosphorylation reaction Methods 0.000 description 6
230000008569 process Effects 0.000 description 6
239000013589 supplement Substances 0.000 description 6
210000003954 umbilical cord Anatomy 0.000 description 6
LAQPKDLYOBZWBT-NYLDSJSYSA-N (2s,4s,5r,6r)-5-acetamido-2-{[(2s,3r,4s,5s,6r)-2-{[(2r,3r,4r,5r)-5-acetamido-1,2-dihydroxy-6-oxo-4-{[(2s,3s,4r,5s,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}hexan-3-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-4-hydroxy-6-[(1r,2r)-1,2,3-trihydrox Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@@H](NC(C)=O)C=O)[C@@H]([C@H](O)CO)O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 LAQPKDLYOBZWBT-NYLDSJSYSA-N 0.000 description 5
101800001318 Capsid protein VP4 Proteins 0.000 description 5
201000009030 Carcinoma Diseases 0.000 description 5
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
108090000581 Leukemia inhibitory factor Proteins 0.000 description 5
108010063737 Myristoylated Alanine-Rich C Kinase Substrate Proteins 0.000 description 5
102000015695 Myristoylated Alanine-Rich C Kinase Substrate Human genes 0.000 description 5
108010057466 NF-kappa B Proteins 0.000 description 5
102000003945 NF-kappa B Human genes 0.000 description 5
102000016611 Proteoglycans Human genes 0.000 description 5
108010067787 Proteoglycans Proteins 0.000 description 5
102100027609 Rho-related GTP-binding protein RhoD Human genes 0.000 description 5
108010023082 activin A Proteins 0.000 description 5
239000002246 antineoplastic agent Substances 0.000 description 5
238000003556 assay Methods 0.000 description 5
239000011575 calcium Substances 0.000 description 5
210000003494 hepatocyte Anatomy 0.000 description 5
230000001965 increasing effect Effects 0.000 description 5
238000011534 incubation Methods 0.000 description 5
238000002955 isolation Methods 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
210000000287 oocyte Anatomy 0.000 description 5
230000036961 partial effect Effects 0.000 description 5
230000003389 potentiating effect Effects 0.000 description 5
108090000765 processed proteins & peptides Proteins 0.000 description 5
230000001172 regenerating effect Effects 0.000 description 5
230000008672 reprogramming Effects 0.000 description 5
238000013341 scale-up Methods 0.000 description 5
210000003491 skin Anatomy 0.000 description 5
230000004083 survival effect Effects 0.000 description 5
238000003786 synthesis reaction Methods 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
JVIPLYCGEZUBIO-UHFFFAOYSA-N 2-(4-fluorophenyl)-1,3-dioxoisoindole-5-carboxylic acid Chemical compound O=C1C2=CC(C(=O)O)=CC=C2C(=O)N1C1=CC=C(F)C=C1 JVIPLYCGEZUBIO-UHFFFAOYSA-N 0.000 description 4
208000026310 Breast neoplasm Diseases 0.000 description 4
206010009944 Colon cancer Diseases 0.000 description 4
102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 4
229920001425 Diethylaminoethyl cellulose Polymers 0.000 description 4
OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 4
102000016349 Myosin Light Chains Human genes 0.000 description 4
108010067385 Myosin Light Chains Proteins 0.000 description 4
241000700159 Rattus Species 0.000 description 4
108010017842 Telomerase Proteins 0.000 description 4
108090000631 Trypsin Proteins 0.000 description 4
102000004142 Trypsin Human genes 0.000 description 4
150000001412 amines Chemical class 0.000 description 4
125000003277 amino group Chemical group 0.000 description 4
210000001185 bone marrow Anatomy 0.000 description 4
229910002091 carbon monoxide Inorganic materials 0.000 description 4
230000024245 cell differentiation Effects 0.000 description 4
230000003833 cell viability Effects 0.000 description 4
230000008859 change Effects 0.000 description 4
230000001419 dependent effect Effects 0.000 description 4
238000001514 detection method Methods 0.000 description 4
238000011161 development Methods 0.000 description 4
230000018109 developmental process Effects 0.000 description 4
230000003828 downregulation Effects 0.000 description 4
239000000284 extract Substances 0.000 description 4
239000012091 fetal bovine serum Substances 0.000 description 4
238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
230000004927 fusion Effects 0.000 description 4
210000003958 hematopoietic stem cell Anatomy 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
210000004185 liver Anatomy 0.000 description 4
210000005229 liver cell Anatomy 0.000 description 4
210000004379 membrane Anatomy 0.000 description 4
239000012528 membrane Substances 0.000 description 4
230000031864 metaphase Effects 0.000 description 4
239000011325 microbead Substances 0.000 description 4
210000001178 neural stem cell Anatomy 0.000 description 4
210000002569 neuron Anatomy 0.000 description 4
230000007935 neutral effect Effects 0.000 description 4
210000000056 organ Anatomy 0.000 description 4
102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 4
108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 4
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
230000000717 retained effect Effects 0.000 description 4
230000011664 signaling Effects 0.000 description 4
DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
239000007787 solid Substances 0.000 description 4
239000000243 solution Substances 0.000 description 4
230000003068 static effect Effects 0.000 description 4
239000012588 trypsin Substances 0.000 description 4
208000024827 Alzheimer disease Diseases 0.000 description 3
241000283690 Bos taurus Species 0.000 description 3
206010006187 Breast cancer Diseases 0.000 description 3
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
208000001333 Colorectal Neoplasms Diseases 0.000 description 3
238000002965 ELISA Methods 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 3
108010003272 Hyaluronate lyase Proteins 0.000 description 3
102000001974 Hyaluronidases Human genes 0.000 description 3
102000004877 Insulin Human genes 0.000 description 3
108090001061 Insulin Proteins 0.000 description 3
208000008839 Kidney Neoplasms Diseases 0.000 description 3
229930182816 L-glutamine Natural products 0.000 description 3
102100032352 Leukemia inhibitory factor Human genes 0.000 description 3
102100035044 Myosin light chain kinase, smooth muscle Human genes 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
206010061535 Ovarian neoplasm Diseases 0.000 description 3
206010061902 Pancreatic neoplasm Diseases 0.000 description 3
208000018737 Parkinson disease Diseases 0.000 description 3
102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 3
108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 3
208000000236 Prostatic Neoplasms Diseases 0.000 description 3
101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 3
241000283984 Rodentia Species 0.000 description 3
102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 3
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
230000009471 action Effects 0.000 description 3
230000004913 activation Effects 0.000 description 3
230000002776 aggregation Effects 0.000 description 3
238000004220 aggregation Methods 0.000 description 3
210000001691 amnion Anatomy 0.000 description 3
239000005557 antagonist Substances 0.000 description 3
229910052791 calcium Inorganic materials 0.000 description 3
230000000747 cardiac effect Effects 0.000 description 3
239000006285 cell suspension Substances 0.000 description 3
238000012512 characterization method Methods 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
210000000038 chest Anatomy 0.000 description 3
238000003501 co-culture Methods 0.000 description 3
208000029742 colonic neoplasm Diseases 0.000 description 3
239000002299 complementary DNA Substances 0.000 description 3
238000005138 cryopreservation Methods 0.000 description 3
230000002559 cytogenic effect Effects 0.000 description 3
235000020776 essential amino acid Nutrition 0.000 description 3
239000003797 essential amino acid Substances 0.000 description 3
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 3
229960005420 etoposide Drugs 0.000 description 3
238000000684 flow cytometry Methods 0.000 description 3
230000006870 function Effects 0.000 description 3
210000004392 genitalia Anatomy 0.000 description 3
210000001654 germ layer Anatomy 0.000 description 3
230000004217 heart function Effects 0.000 description 3
230000002440 hepatic effect Effects 0.000 description 3
229960002773 hyaluronidase Drugs 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
229940125396 insulin Drugs 0.000 description 3
230000003834 intracellular effect Effects 0.000 description 3
208000032839 leukemia Diseases 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
239000007788 liquid Substances 0.000 description 3
208000020816 lung neoplasm Diseases 0.000 description 3
108020004999 messenger RNA Proteins 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
230000000877 morphologic effect Effects 0.000 description 3
230000001537 neural effect Effects 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
210000004248 oligodendroglia Anatomy 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
238000012552 review Methods 0.000 description 3
231100000241 scar Toxicity 0.000 description 3
238000012216 screening Methods 0.000 description 3
238000010186 staining Methods 0.000 description 3
230000008093 supporting effect Effects 0.000 description 3
150000003512 tertiary amines Chemical class 0.000 description 3
125000003396 thiol group Chemical group [H]S* 0.000 description 3
238000001890 transfection Methods 0.000 description 3
238000012546 transfer Methods 0.000 description 3
230000035899 viability Effects 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
230000003442 weekly effect Effects 0.000 description 3
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
OGBITGGJALIXMB-UHFFFAOYSA-N 1-pyridin-4-yl-1-(2,4,6-trichlorophenyl)urea Chemical compound ClC=1C=C(Cl)C=C(Cl)C=1N(C(=O)N)C1=CC=NC=C1 OGBITGGJALIXMB-UHFFFAOYSA-N 0.000 description 2
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
229920000936 Agarose Polymers 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 2
101100356682 Caenorhabditis elegans rho-1 gene Proteins 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
241000283707 Capra Species 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
241000700199 Cavia porcellus Species 0.000 description 2
206010008342 Cervix carcinoma Diseases 0.000 description 2
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
229920002271 DEAE-Sepharose Polymers 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 2
SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
206010019280 Heart failures Diseases 0.000 description 2
241000282412 Homo Species 0.000 description 2
101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 description 2
101001005128 Homo sapiens LIM domain kinase 1 Proteins 0.000 description 2
101001000061 Homo sapiens Protein phosphatase 1 regulatory subunit 12A Proteins 0.000 description 2
108010002352 Interleukin-1 Proteins 0.000 description 2
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
102100026023 LIM domain kinase 1 Human genes 0.000 description 2
102000004058 Leukemia inhibitory factor Human genes 0.000 description 2
206010058467 Lung neoplasm malignant Diseases 0.000 description 2
206010025323 Lymphomas Diseases 0.000 description 2
102000043136 MAP kinase family Human genes 0.000 description 2
108091054455 MAP kinase family Proteins 0.000 description 2
229940122696 MAP kinase inhibitor Drugs 0.000 description 2
241001529936 Murinae Species 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
101710198035 Myosin light chain kinase, smooth muscle Proteins 0.000 description 2
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
206010033128 Ovarian cancer Diseases 0.000 description 2
101150020891 PRKCA gene Proteins 0.000 description 2
229930012538 Paclitaxel Natural products 0.000 description 2
239000004372 Polyvinyl alcohol Substances 0.000 description 2
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
206010060862 Prostate cancer Diseases 0.000 description 2
102100036547 Protein phosphatase 1 regulatory subunit 12A Human genes 0.000 description 2
101150111584 RHOA gene Proteins 0.000 description 2
206010038389 Renal cancer Diseases 0.000 description 2
206010039491 Sarcoma Diseases 0.000 description 2
208000000453 Skin Neoplasms Diseases 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
101100277598 Sorghum bicolor DES3 gene Proteins 0.000 description 2
108010073771 Soybean Proteins Proteins 0.000 description 2
208000005718 Stomach Neoplasms Diseases 0.000 description 2
241000282898 Sus scrofa Species 0.000 description 2
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
108010018242 Transcription Factor AP-1 Proteins 0.000 description 2
102100023132 Transcription factor Jun Human genes 0.000 description 2
102000004338 Transferrin Human genes 0.000 description 2
108090000901 Transferrin Proteins 0.000 description 2
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
239000000654 additive Substances 0.000 description 2
210000001789 adipocyte Anatomy 0.000 description 2
229940009456 adriamycin Drugs 0.000 description 2
230000004931 aggregating effect Effects 0.000 description 2
238000010171 animal model Methods 0.000 description 2
239000003957 anion exchange resin Substances 0.000 description 2
238000013459 approach Methods 0.000 description 2
125000001769 aryl amino group Chemical group 0.000 description 2
210000002469 basement membrane Anatomy 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
210000000988 bone and bone Anatomy 0.000 description 2
229940098773 bovine serum albumin Drugs 0.000 description 2
239000000969 carrier Substances 0.000 description 2
210000000845 cartilage Anatomy 0.000 description 2
230000003197 catalytic effect Effects 0.000 description 2
210000005056 cell body Anatomy 0.000 description 2
230000022131 cell cycle Effects 0.000 description 2
230000012292 cell migration Effects 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
201000010881 cervical cancer Diseases 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 2
230000005757 colony formation Effects 0.000 description 2
230000002860 competitive effect Effects 0.000 description 2
210000002808 connective tissue Anatomy 0.000 description 2
239000002254 cytotoxic agent Substances 0.000 description 2
231100000599 cytotoxic agent Toxicity 0.000 description 2
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
230000007423 decrease Effects 0.000 description 2
230000002950 deficient Effects 0.000 description 2
210000004443 dendritic cell Anatomy 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
229960002986 dinoprostone Drugs 0.000 description 2
150000002016 disaccharides Chemical group 0.000 description 2
238000002224 dissection Methods 0.000 description 2
238000009826 distribution Methods 0.000 description 2
238000007877 drug screening Methods 0.000 description 2
230000003511 endothelial effect Effects 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
230000007613 environmental effect Effects 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
210000002219 extraembryonic membrane Anatomy 0.000 description 2
239000012894 fetal calf serum Substances 0.000 description 2
210000003754 fetus Anatomy 0.000 description 2
229960002949 fluorouracil Drugs 0.000 description 2
210000001650 focal adhesion Anatomy 0.000 description 2
239000000499 gel Substances 0.000 description 2
238000001502 gel electrophoresis Methods 0.000 description 2
239000008103 glucose Substances 0.000 description 2
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
150000004676 glycans Chemical class 0.000 description 2
210000002149 gonad Anatomy 0.000 description 2
206010073071 hepatocellular carcinoma Diseases 0.000 description 2
210000004754 hybrid cell Anatomy 0.000 description 2
239000000413 hydrolysate Substances 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
208000014674 injury Diseases 0.000 description 2
230000003993 interaction Effects 0.000 description 2
230000009545 invasion Effects 0.000 description 2
235000015110 jellies Nutrition 0.000 description 2
239000008274 jelly Substances 0.000 description 2
201000010982 kidney cancer Diseases 0.000 description 2
238000000021 kinase assay Methods 0.000 description 2
229940043355 kinase inhibitor Drugs 0.000 description 2
210000003041 ligament Anatomy 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
208000014018 liver neoplasm Diseases 0.000 description 2
210000005228 liver tissue Anatomy 0.000 description 2
201000005202 lung cancer Diseases 0.000 description 2
210000005265 lung cell Anatomy 0.000 description 2
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
230000035800 maturation Effects 0.000 description 2
SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
229960001924 melphalan Drugs 0.000 description 2
125000005395 methacrylic acid group Chemical group 0.000 description 2
229960000485 methotrexate Drugs 0.000 description 2
238000001000 micrograph Methods 0.000 description 2
239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 2
210000002241 neurite Anatomy 0.000 description 2
208000015122 neurodegenerative disease Diseases 0.000 description 2
208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
230000005937 nuclear translocation Effects 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
210000004940 nucleus Anatomy 0.000 description 2
229960001592 paclitaxel Drugs 0.000 description 2
201000002528 pancreatic cancer Diseases 0.000 description 2
208000008443 pancreatic carcinoma Diseases 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
238000007747 plating Methods 0.000 description 2
229920002451 polyvinyl alcohol Polymers 0.000 description 2
230000035935 pregnancy Effects 0.000 description 2
XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 2
238000011536 re-plating Methods 0.000 description 2
230000008929 regeneration Effects 0.000 description 2
238000011069 regeneration method Methods 0.000 description 2
238000007634 remodeling Methods 0.000 description 2
230000008439 repair process Effects 0.000 description 2
230000007017 scission Effects 0.000 description 2
239000012679 serum free medium Substances 0.000 description 2
230000019491 signal transduction Effects 0.000 description 2
235000019710 soybean protein Nutrition 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
229920002994 synthetic fiber Polymers 0.000 description 2
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
210000002435 tendon Anatomy 0.000 description 2
238000012360 testing method Methods 0.000 description 2
210000001550 testis Anatomy 0.000 description 2
210000003014 totipotent stem cell Anatomy 0.000 description 2
239000003053 toxin Substances 0.000 description 2
231100000765 toxin Toxicity 0.000 description 2
108700012359 toxins Proteins 0.000 description 2
239000012581 transferrin Substances 0.000 description 2
230000005945 translocation Effects 0.000 description 2
230000008733 trauma Effects 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
241001430294 unidentified retrovirus Species 0.000 description 2
239000013598 vector Substances 0.000 description 2
229960004528 vincristine Drugs 0.000 description 2
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
239000013603 viral vector Substances 0.000 description 2
238000001262 western blot Methods 0.000 description 2
NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 1
FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 1
WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
QBACGOWRJDBXSG-ONEGZZNKSA-N (e)-n-[4-(3-bromo-4-chloroanilino)pyrido[3,4-d]pyrimidin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound N1=CN=C2C=NC(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(Cl)C(Br)=C1 QBACGOWRJDBXSG-ONEGZZNKSA-N 0.000 description 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
101710175516 14 kDa zinc-binding protein Proteins 0.000 description 1
WFIYPADYPQQLNN-UHFFFAOYSA-N 2-[2-(4-bromopyrazol-1-yl)ethyl]isoindole-1,3-dione Chemical compound C1=C(Br)C=NN1CCN1C(=O)C2=CC=CC=C2C1=O WFIYPADYPQQLNN-UHFFFAOYSA-N 0.000 description 1
MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
LQXSRESCWSLLGA-UHFFFAOYSA-N 3-pyridin-4-yl-1H-indole Chemical compound N1=CC=C(C=C1)C1=CNC2=CC=CC=C12.N1=CC=C(C=C1)C1=CNC2=CC=CC=C12 LQXSRESCWSLLGA-UHFFFAOYSA-N 0.000 description 1
LLSFXOUAPAZFIV-SNVBAGLBSA-N 4-[(1r)-1-aminoethyl]-n-pyridin-4-ylbenzamide Chemical compound C1=CC([C@H](N)C)=CC=C1C(=O)NC1=CC=NC=C1 LLSFXOUAPAZFIV-SNVBAGLBSA-N 0.000 description 1
TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
ZEWWMQPOPGVFGX-UHFFFAOYSA-N 6,7-diamino-2h-phthalazin-1-one Chemical class C1=NNC(=O)C2=C1C=C(N)C(N)=C2 ZEWWMQPOPGVFGX-UHFFFAOYSA-N 0.000 description 1
102000015693 Actin Depolymerizing Factors Human genes 0.000 description 1
108010038798 Actin Depolymerizing Factors Proteins 0.000 description 1
102000007469 Actins Human genes 0.000 description 1
108010085238 Actins Proteins 0.000 description 1
208000007788 Acute Liver Failure Diseases 0.000 description 1
206010000804 Acute hepatic failure Diseases 0.000 description 1
102100036601 Aggrecan core protein Human genes 0.000 description 1
108010067219 Aggrecans Proteins 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
102400000068 Angiostatin Human genes 0.000 description 1
108010079709 Angiostatins Proteins 0.000 description 1
208000032467 Aplastic anaemia Diseases 0.000 description 1
206010003225 Arteriospasm coronary Diseases 0.000 description 1
206010003402 Arthropod sting Diseases 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
108010006654 Bleomycin Proteins 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 1
102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 1
208000018084 Bone neoplasm Diseases 0.000 description 1
208000003174 Brain Neoplasms Diseases 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
DWTNLZZEPSCAIH-VOMCLLRMSA-N C1CC([C@H](N)C)CCC1C(=O)NC1=CC=NC2=C1C=CN2 Chemical compound C1CC([C@H](N)C)CCC1C(=O)NC1=CC=NC2=C1C=CN2 DWTNLZZEPSCAIH-VOMCLLRMSA-N 0.000 description 1
108050007957 Cadherin Proteins 0.000 description 1
101100257359 Caenorhabditis elegans sox-2 gene Proteins 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
108010026870 Calcium-Calmodulin-Dependent Protein Kinases Proteins 0.000 description 1
102000019025 Calcium-Calmodulin-Dependent Protein Kinases Human genes 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
206010008354 Cervix neoplasm Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
108010042086 Collagen Type IV Proteins 0.000 description 1
102000004266 Collagen Type IV Human genes 0.000 description 1
102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 description 1
208000003890 Coronary Vasospasm Diseases 0.000 description 1
108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 1
238000007399 DNA isolation Methods 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
108010092160 Dactinomycin Proteins 0.000 description 1
102000004237 Decorin Human genes 0.000 description 1
108090000738 Decorin Proteins 0.000 description 1
NNJPGOLRFBJNIW-UHFFFAOYSA-N Demecolcine Natural products C1=C(OC)C(=O)C=C2C(NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-UHFFFAOYSA-N 0.000 description 1
229920000045 Dermatan sulfate Polymers 0.000 description 1
102100030074 Dickkopf-related protein 1 Human genes 0.000 description 1
206010013142 Disinhibition Diseases 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
206010014733 Endometrial cancer Diseases 0.000 description 1
206010014759 Endometrial neoplasm Diseases 0.000 description 1
108010079505 Endostatins Proteins 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
229930189413 Esperamicin Natural products 0.000 description 1
208000013452 Fallopian tube neoplasm Diseases 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
102000016621 Focal Adhesion Protein-Tyrosine Kinases Human genes 0.000 description 1
108010067715 Focal Adhesion Protein-Tyrosine Kinases Proteins 0.000 description 1
108090000852 Forkhead Transcription Factors Proteins 0.000 description 1
102000004315 Forkhead Transcription Factors Human genes 0.000 description 1
102100037060 Forkhead box protein D3 Human genes 0.000 description 1
239000001828 Gelatine Substances 0.000 description 1
206010018338 Glioma Diseases 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
208000013875 Heart injury Diseases 0.000 description 1
208000002250 Hematologic Neoplasms Diseases 0.000 description 1
102100027618 Heme transporter HRG1 Human genes 0.000 description 1
101150094793 Hes3 gene Proteins 0.000 description 1
208000017604 Hodgkin disease Diseases 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
101000864646 Homo sapiens Dickkopf-related protein 1 Proteins 0.000 description 1
101001052035 Homo sapiens Fibroblast growth factor 2 Proteins 0.000 description 1
101001029308 Homo sapiens Forkhead box protein D3 Proteins 0.000 description 1
101001081412 Homo sapiens Heme transporter HRG1 Proteins 0.000 description 1
101001139134 Homo sapiens Krueppel-like factor 4 Proteins 0.000 description 1
101001042360 Homo sapiens LIM domain kinase 2 Proteins 0.000 description 1
101000595198 Homo sapiens Podocalyxin Proteins 0.000 description 1
101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 1
101000669921 Homo sapiens Rho-associated protein kinase 2 Proteins 0.000 description 1
101000843572 Homo sapiens Transcription factor HES-2 Proteins 0.000 description 1
101000843569 Homo sapiens Transcription factor HES-3 Proteins 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
206010065390 Inflammatory pain Diseases 0.000 description 1
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
208000003456 Juvenile Arthritis Diseases 0.000 description 1
206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
229920000288 Keratan sulfate Polymers 0.000 description 1
102100020677 Krueppel-like factor 4 Human genes 0.000 description 1
108700021430 Kruppel-Like Factor 4 Proteins 0.000 description 1
102100021756 LIM domain kinase 2 Human genes 0.000 description 1
108010089704 Lim Kinases Proteins 0.000 description 1
102000008020 Lim Kinases Human genes 0.000 description 1
206010067125 Liver injury Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
206010064912 Malignant transformation Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
229930192392 Mitomycin Natural products 0.000 description 1
101100257363 Mus musculus Sox2 gene Proteins 0.000 description 1
102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
108010074596 Myosin-Light-Chain Kinase Proteins 0.000 description 1
108010037801 Myosin-Light-Chain Phosphatase Proteins 0.000 description 1
102000011131 Myosin-Light-Chain Phosphatase Human genes 0.000 description 1
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
KYIMHWNKQXQBDG-UHFFFAOYSA-N N=C=O.N=C=O.CCCCCC Chemical compound N=C=O.N=C=O.CCCCCC KYIMHWNKQXQBDG-UHFFFAOYSA-N 0.000 description 1
206010029240 Neuritis Diseases 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
208000009905 Neurofibromatoses Diseases 0.000 description 1
102000008763 Neurofilament Proteins Human genes 0.000 description 1
108010088373 Neurofilament Proteins Proteins 0.000 description 1
238000000636 Northern blotting Methods 0.000 description 1
102000002584 Octamer Transcription Factor-3 Human genes 0.000 description 1
108010068425 Octamer Transcription Factor-3 Proteins 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
102000004067 Osteocalcin Human genes 0.000 description 1
108090000573 Osteocalcin Proteins 0.000 description 1
102100029181 PDZ and LIM domain protein 5 Human genes 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
241001494479 Pecora Species 0.000 description 1
208000006735 Periostitis Diseases 0.000 description 1
206010057249 Phagocytosis Diseases 0.000 description 1
244000046052 Phaseolus vulgaris Species 0.000 description 1
235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
102000010995 Pleckstrin homology domains Human genes 0.000 description 1
108050001185 Pleckstrin homology domains Proteins 0.000 description 1
102100036031 Podocalyxin Human genes 0.000 description 1
102100024028 Progonadoliberin-1 Human genes 0.000 description 1
108010059712 Pronase Proteins 0.000 description 1
108010009736 Protein Hydrolysates Proteins 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
101710150336 Protein Rex Proteins 0.000 description 1
102100021557 Protein kinase C iota type Human genes 0.000 description 1
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
239000012564 Q sepharose fast flow resin Substances 0.000 description 1
239000012614 Q-Sepharose Substances 0.000 description 1
101150058540 RAC1 gene Proteins 0.000 description 1
238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
102100022122 Ras-related C3 botulinum toxin substrate 1 Human genes 0.000 description 1
101001081402 Rattus norvegicus Histidine-rich glycoprotein Proteins 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
208000015634 Rectal Neoplasms Diseases 0.000 description 1
108700008625 Reporter Genes Proteins 0.000 description 1
102100039313 Rho-associated protein kinase 1 Human genes 0.000 description 1
101710088411 Rho-associated protein kinase 1 Proteins 0.000 description 1
102100039314 Rho-associated protein kinase 2 Human genes 0.000 description 1
101150054980 Rhob gene Proteins 0.000 description 1
108060006706 SRC Proteins 0.000 description 1
102000001332 SRC Human genes 0.000 description 1
206010061934 Salivary gland cancer Diseases 0.000 description 1
229940124639 Selective inhibitor Drugs 0.000 description 1
BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
206010070834 Sensitisation Diseases 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
206010041067 Small cell lung cancer Diseases 0.000 description 1
108020004459 Small interfering RNA Proteins 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
238000002105 Southern blotting Methods 0.000 description 1
241000194017 Streptococcus Species 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
101710172711 Structural protein Proteins 0.000 description 1
OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 1
101150052863 THY1 gene Proteins 0.000 description 1
208000024313 Testicular Neoplasms Diseases 0.000 description 1
FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
208000024770 Thyroid neoplasm Diseases 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
102100030772 Transcription factor HES-2 Human genes 0.000 description 1
102100030773 Transcription factor HES-3 Human genes 0.000 description 1
101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
206010047741 Vulval cancer Diseases 0.000 description 1
102000044880 Wnt3A Human genes 0.000 description 1
108700013515 Wnt3A Proteins 0.000 description 1
DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
210000002718 aborted fetus Anatomy 0.000 description 1
239000002253 acid Substances 0.000 description 1
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
239000012190 activator Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000009692 acute damage Effects 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
238000011166 aliquoting Methods 0.000 description 1
229930013930 alkaloid Natural products 0.000 description 1
229960003896 aminopterin Drugs 0.000 description 1
230000003321 amplification Effects 0.000 description 1
238000004873 anchoring Methods 0.000 description 1
230000003322 aneuploid effect Effects 0.000 description 1
208000036878 aneuploidy Diseases 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
230000003257 anti-anginal effect Effects 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
230000000708 anti-progestin effect Effects 0.000 description 1
230000003356 anti-rheumatic effect Effects 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
229940100197 antimetabolite Drugs 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
239000003418 antiprogestin Substances 0.000 description 1
239000003435 antirheumatic agent Substances 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
238000003149 assay kit Methods 0.000 description 1
210000001130 astrocyte Anatomy 0.000 description 1
VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
210000001841 basilar artery Anatomy 0.000 description 1
230000006399 behavior Effects 0.000 description 1
150000001558 benzoic acid derivatives Chemical class 0.000 description 1
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
125000002619 bicyclic group Chemical group 0.000 description 1
210000000013 bile duct Anatomy 0.000 description 1
210000003445 biliary tract Anatomy 0.000 description 1
238000010364 biochemical engineering Methods 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
239000012620 biological material Substances 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
201000000053 blastoma Diseases 0.000 description 1
229960001561 bleomycin Drugs 0.000 description 1
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
210000003995 blood forming stem cell Anatomy 0.000 description 1
101150067309 bmp4 gene Proteins 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
208000015322 bone marrow disease Diseases 0.000 description 1
238000010322 bone marrow transplantation Methods 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
229960002092 busulfan Drugs 0.000 description 1
239000000480 calcium channel blocker Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
229960004562 carboplatin Drugs 0.000 description 1
XREUEWVEMYWFFA-CSKJXFQVSA-N carminomycin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XREUEWVEMYWFFA-CSKJXFQVSA-N 0.000 description 1
229930188550 carminomycin Natural products 0.000 description 1
XREUEWVEMYWFFA-UHFFFAOYSA-N carminomycin I Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XREUEWVEMYWFFA-UHFFFAOYSA-N 0.000 description 1
229950001725 carubicin Drugs 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
230000011712 cell development Effects 0.000 description 1
230000009087 cell motility Effects 0.000 description 1
238000002659 cell therapy Methods 0.000 description 1
230000005754 cellular signaling Effects 0.000 description 1
210000004720 cerebrum Anatomy 0.000 description 1
238000012412 chemical coupling Methods 0.000 description 1
FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 1
229940106681 chloroacetic acid Drugs 0.000 description 1
210000001612 chondrocyte Anatomy 0.000 description 1
229940059329 chondroitin sulfate Drugs 0.000 description 1
239000012504 chromatography matrix Substances 0.000 description 1
239000012539 chromatography resin Substances 0.000 description 1
239000013611 chromosomal DNA Substances 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
208000019069 chronic childhood arthritis Diseases 0.000 description 1
230000009693 chronic damage Effects 0.000 description 1
235000019506 cigar Nutrition 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
238000010372 cloning stem cell Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
239000002131 composite material Substances 0.000 description 1
230000001143 conditioned effect Effects 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
238000011109 contamination Methods 0.000 description 1
238000010924 continuous production Methods 0.000 description 1
230000008602 contraction Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
201000011634 coronary artery vasospasm Diseases 0.000 description 1
239000007822 coupling agent Substances 0.000 description 1
239000003431 cross linking reagent Substances 0.000 description 1
208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
QPJDMGCKMHUXFD-UHFFFAOYSA-N cyanogen chloride Chemical compound ClC#N QPJDMGCKMHUXFD-UHFFFAOYSA-N 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
210000004292 cytoskeleton Anatomy 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
229960000640 dactinomycin Drugs 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
229940051593 dermatan sulfate Drugs 0.000 description 1
210000004207 dermis Anatomy 0.000 description 1
238000013461 design Methods 0.000 description 1
238000010586 diagram Methods 0.000 description 1
230000003205 diastolic effect Effects 0.000 description 1
RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
230000029087 digestion Effects 0.000 description 1
238000007865 diluting Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
108010007093 dispase Proteins 0.000 description 1
AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 1
238000011833 dog model Methods 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000000857 drug effect Effects 0.000 description 1
238000003255 drug test Methods 0.000 description 1
230000008406 drug-drug interaction Effects 0.000 description 1
230000002900 effect on cell Effects 0.000 description 1
230000010102 embolization Effects 0.000 description 1
230000013020 embryo development Effects 0.000 description 1
201000008184 embryoma Diseases 0.000 description 1
210000002308 embryonic cell Anatomy 0.000 description 1
238000009261 endocrine therapy Methods 0.000 description 1
201000003914 endometrial carcinoma Diseases 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
230000001973 epigenetic effect Effects 0.000 description 1
206010015037 epilepsy Diseases 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
210000003999 epithelial cell of bile duct Anatomy 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
230000003492 excitotoxic effect Effects 0.000 description 1
231100000063 excitotoxicity Toxicity 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
230000028023 exocytosis Effects 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
208000024519 eye neoplasm Diseases 0.000 description 1
210000000887 face Anatomy 0.000 description 1
102000034240 fibrous proteins Human genes 0.000 description 1
108091005899 fibrous proteins Proteins 0.000 description 1
239000010408 film Substances 0.000 description 1
230000009969 flowable effect Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
210000003953 foreskin Anatomy 0.000 description 1
239000012634 fragment Substances 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
239000007789 gas Substances 0.000 description 1
206010017758 gastric cancer Diseases 0.000 description 1
238000005227 gel permeation chromatography Methods 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
230000009368 gene silencing by RNA Effects 0.000 description 1
208000005017 glioblastoma Diseases 0.000 description 1
150000002337 glycosamines Chemical class 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
239000010931 gold Substances 0.000 description 1
150000002344 gold compounds Chemical class 0.000 description 1
230000002710 gonadal effect Effects 0.000 description 1
XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 1
210000000224 granular leucocyte Anatomy 0.000 description 1
230000003394 haemopoietic effect Effects 0.000 description 1
201000010536 head and neck cancer Diseases 0.000 description 1
208000014829 head and neck neoplasm Diseases 0.000 description 1
210000002064 heart cell Anatomy 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000009033 hematopoietic malignancy Effects 0.000 description 1
231100000234 hepatic damage Toxicity 0.000 description 1
210000004024 hepatic stellate cell Anatomy 0.000 description 1
231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
230000001744 histochemical effect Effects 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
229940099552 hyaluronan Drugs 0.000 description 1
KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
229940014041 hyaluronate Drugs 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
229960001101 ifosfamide Drugs 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
238000003365 immunocytochemistry Methods 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
230000002055 immunohistochemical effect Effects 0.000 description 1
238000011532 immunohistochemical staining Methods 0.000 description 1
238000003364 immunohistochemistry Methods 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
238000002513 implantation Methods 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
102000006495 integrins Human genes 0.000 description 1
108010044426 integrins Proteins 0.000 description 1
230000008611 intercellular interaction Effects 0.000 description 1
210000004692 intercellular junction Anatomy 0.000 description 1
208000001286 intracranial vasospasm Diseases 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
210000004153 islets of langerhan Anatomy 0.000 description 1
AWJUIBRHMBBTKR-UHFFFAOYSA-N iso-quinoline Natural products C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 1
201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
210000001865 kupffer cell Anatomy 0.000 description 1
238000011031 large-scale manufacturing process Methods 0.000 description 1
230000003902 lesion Effects 0.000 description 1
208000036546 leukodystrophy Diseases 0.000 description 1
239000003446 ligand Substances 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
201000007270 liver cancer Diseases 0.000 description 1
230000008818 liver damage Effects 0.000 description 1
230000003908 liver function Effects 0.000 description 1
244000144972 livestock Species 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
230000036212 malign transformation Effects 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
210000004216 mammary stem cell Anatomy 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
239000012577 media supplement Substances 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
230000003821 menstrual periods Effects 0.000 description 1
210000000713 mesentery Anatomy 0.000 description 1
210000001704 mesoblast Anatomy 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
238000002493 microarray Methods 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
229960001156 mitoxantrone Drugs 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
238000004264 monolayer culture Methods 0.000 description 1
230000004660 morphological change Effects 0.000 description 1
210000000472 morula Anatomy 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
210000002464 muscle smooth vascular Anatomy 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
JRVSFZKYQCETAH-OAHLLOKOSA-N n-[(1r)-1-(3-methoxyphenyl)ethyl]-4-pyridin-4-ylbenzamide Chemical compound COC1=CC=CC([C@@H](C)NC(=O)C=2C=CC(=CC=2)C=2C=CN=CC=2)=C1 JRVSFZKYQCETAH-OAHLLOKOSA-N 0.000 description 1
229950006780 n-acetylglucosamine Drugs 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
210000003061 neural cell Anatomy 0.000 description 1
210000000933 neural crest Anatomy 0.000 description 1
210000001020 neural plate Anatomy 0.000 description 1
210000005155 neural progenitor cell Anatomy 0.000 description 1
208000004296 neuralgia Diseases 0.000 description 1
210000003757 neuroblast Anatomy 0.000 description 1
201000004931 neurofibromatosis Diseases 0.000 description 1
210000005044 neurofilament Anatomy 0.000 description 1
208000021722 neuropathic pain Diseases 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
230000007823 neuropathy Effects 0.000 description 1
230000003957 neurotransmitter release Effects 0.000 description 1
229960003753 nitric oxide Drugs 0.000 description 1
JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
108700007229 noggin Proteins 0.000 description 1
102000045246 noggin Human genes 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
238000002515 oligonucleotide synthesis Methods 0.000 description 1
230000006548 oncogenic transformation Effects 0.000 description 1
238000000399 optical microscopy Methods 0.000 description 1
210000000963 osteoblast Anatomy 0.000 description 1
210000004409 osteocyte Anatomy 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
210000004738 parenchymal cell Anatomy 0.000 description 1
230000008186 parthenogenesis Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000018052 penile erection Effects 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
210000003460 periosteum Anatomy 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
230000008782 phagocytosis Effects 0.000 description 1
239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 description 1
150000003905 phosphatidylinositols Chemical class 0.000 description 1
229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 1
239000003757 phosphotransferase inhibitor Substances 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
229960002797 pitavastatin Drugs 0.000 description 1
210000002826 placenta Anatomy 0.000 description 1
108010000685 platelet-derived growth factor AB Proteins 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
238000003752 polymerase chain reaction Methods 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
208000015768 polyposis Diseases 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
150000004804 polysaccharides Polymers 0.000 description 1
231100000683 possible toxicity Toxicity 0.000 description 1
150000003141 primary amines Chemical group 0.000 description 1
239000000186 progesterone Substances 0.000 description 1
229960003387 progesterone Drugs 0.000 description 1
239000000583 progesterone congener Substances 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
210000004129 prosencephalon Anatomy 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
239000003909 protein kinase inhibitor Substances 0.000 description 1
238000011002 quantification Methods 0.000 description 1
238000010791 quenching Methods 0.000 description 1
230000000171 quenching effect Effects 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000011552 rat model Methods 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
230000004044 response Effects 0.000 description 1
239000013037 reversible inhibitor Substances 0.000 description 1
238000005096 rolling process Methods 0.000 description 1
201000003804 salivary gland carcinoma Diseases 0.000 description 1
235000013580 sausages Nutrition 0.000 description 1
150000003335 secondary amines Chemical group 0.000 description 1
229910052711 selenium Inorganic materials 0.000 description 1
239000011669 selenium Substances 0.000 description 1
229940091258 selenium supplement Drugs 0.000 description 1
229940055619 selenocysteine Drugs 0.000 description 1
ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 1
235000016491 selenocysteine Nutrition 0.000 description 1
230000009758 senescence Effects 0.000 description 1
230000008313 sensitization Effects 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
238000007873 sieving Methods 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
231100000188 sister chromatid exchange Toxicity 0.000 description 1
201000000849 skin cancer Diseases 0.000 description 1
210000004927 skin cell Anatomy 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
208000000587 small cell lung carcinoma Diseases 0.000 description 1
229940126586 small molecule drug Drugs 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
230000016160 smooth muscle contraction Effects 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
229940054269 sodium pyruvate Drugs 0.000 description 1
YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
239000011343 solid material Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
206010041823 squamous cell carcinoma Diseases 0.000 description 1
208000017572 squamous cell neoplasm Diseases 0.000 description 1
238000012289 standard assay Methods 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
201000011549 stomach cancer Diseases 0.000 description 1
238000003860 storage Methods 0.000 description 1
210000003518 stress fiber Anatomy 0.000 description 1
210000002536 stromal cell Anatomy 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
230000008961 swelling Effects 0.000 description 1
229960001603 tamoxifen Drugs 0.000 description 1
229940063683 taxotere Drugs 0.000 description 1
NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
229960001278 teniposide Drugs 0.000 description 1
208000001608 teratocarcinoma Diseases 0.000 description 1
UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
239000010409 thin film Substances 0.000 description 1
229960001196 thiotepa Drugs 0.000 description 1
235000008521 threonine Nutrition 0.000 description 1
150000003588 threonines Chemical class 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
201000002510 thyroid cancer Diseases 0.000 description 1
239000003104 tissue culture media Substances 0.000 description 1
208000037816 tissue injury Diseases 0.000 description 1
230000017423 tissue regeneration Effects 0.000 description 1
108091008023 transcriptional regulators Proteins 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
230000032258 transport Effects 0.000 description 1
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
210000000143 trophectoderm cell Anatomy 0.000 description 1
210000002993 trophoblast Anatomy 0.000 description 1
208000029387 trophoblastic neoplasm Diseases 0.000 description 1
201000005112 urinary bladder cancer Diseases 0.000 description 1
229940124549 vasodilator Drugs 0.000 description 1
239000003071 vasodilator agent Substances 0.000 description 1
230000002861 ventricular Effects 0.000 description 1
229960003048 vinblastine Drugs 0.000 description 1
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
229960002066 vinorelbine Drugs 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
210000004127 vitreous body Anatomy 0.000 description 1
201000005102 vulva cancer Diseases 0.000 description 1
210000004340 zona pellucida Anatomy 0.000 description 1